An Open Label, Multicenter Phase 1-2 Study to Investigate the Effectiveness, Safety and Immunogenicity of a Monotherapy With Intradermal IMA910 Plus GM-CSF Following Pre-Treatment With Low-Dose Cyclophosphamide in Advanced Colorectal Carcinoma Patients Who Have Successfully Completed a 12 Week First-Line Treatment With Oxaliplatin-Based Chemotherapy.

Trial Profile

An Open Label, Multicenter Phase 1-2 Study to Investigate the Effectiveness, Safety and Immunogenicity of a Monotherapy With Intradermal IMA910 Plus GM-CSF Following Pre-Treatment With Low-Dose Cyclophosphamide in Advanced Colorectal Carcinoma Patients Who Have Successfully Completed a 12 Week First-Line Treatment With Oxaliplatin-Based Chemotherapy.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Sep 2015

At a glance

  • Drugs IMA 910 (Primary) ; Cyclophosphamide; Granulocyte macrophage colony stimulating factor; Imiquimod
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors immatics biotechnologies GmbH
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Jul 2012 Planned end date changed from 1 Jul 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top